NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
Clinical Trials
144 trialsNCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT05321316 2026-03-04
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05436093 2026-03-04
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT05976763 2026-03-04
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06502691 2026-03-02
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT02125786 2026-02-24
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT07285993 2026-02-13
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT04016818 2026-02-10
Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution
Stanford University
Phase EARLY_PHASE1 Not yet recruiting
NCT05775939 2026-02-10
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
Thomas Jefferson University
Phase NA Recruiting
NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04251481 2026-01-22
Diffusion MRI for Head and Neck Cancer
NYU Langone Health
Phase NA Active not recruiting
NCT07097363 2026-01-15
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Recruiting
NCT04333537 2026-01-14
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NRG Oncology
Phase 2/3 Recruiting
NCT02213497 2026-01-08
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Active not recruiting
NCT06385652 2026-01-06
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT07293247 2025-12-22
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Alliance for Clinical Trials in Oncology
Phase 2 Not yet recruiting
NCT05455697 2025-12-18
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington
Phase 1/2 Recruiting
NCT01697527 2025-11-24
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07089641 2025-11-24
ERAS801-SARG
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT05844306 2025-11-19
RefleXion PET/CT Imaging Performance in Patients With Various Malignancies
City of Hope Medical Center
Phase NA Suspended
NCT05892393 2025-11-12
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT02130492 2025-10-23
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT03604315 2025-10-14
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04147494 2025-08-12
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04457258 2025-08-12
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06383598 2025-07-15
PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors
Peking University Cancer Hospital & Institute
Phase NA Recruiting
NCT06632860 2025-07-09
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT06815029 2025-06-26
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
Phase 1 Recruiting
NCT07023848 2025-06-17
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1 Enrolling by invitation
NCT07023861 2025-06-17
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1 Enrolling by invitation
NCT06717113 2025-06-06
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT06956391 2025-06-04
Ultralow Dose PET Imaging of 18F-FDG Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT02810873 2025-05-04
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
Thomas Jefferson University
Phase NA Terminated
NCT03824535 2025-04-09
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Stanford University
Phase 2 Completed
NCT06630845 2025-03-20
Comparison of Whole Body DWI to FDG PET
University of California, San Francisco
Phase NA Recruiting
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06723665 2025-01-24
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
Affiliated Hospital of Jiangnan University
Phase NA Enrolling by invitation
NCT06715020 2024-12-04
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
Peking University Cancer Hospital & Institute
Phase NA Not yet recruiting
NCT02317783 2024-11-20
Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
University of Utah
Phase 2 Terminated
NCT03732352 2024-11-12
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT01246869 2024-10-01
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
University of Utah
Phase 1 Terminated
NCT06429891 2024-08-22
Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
Peking University Cancer Hospital & Institute
Phase NA Recruiting